Objectives Multiple myeloma (MM) patients report high symptom burden and reduced health‐
related quality of life (HRQ oL) compared to patients with other haematological …

PURPOSE Two anti-CD19 chimeric antigen receptor T-cell (CAR-T) therapies are approved
for diffuse large B-cell lymphoma, axicabtagene ciloleucel (axi-cel) and tisagenlecleucel; …

Introduction Treatment advances in multiple myeloma have increased expected survival
from months to years for some patients. Alongside improved survival emerges a need to …

Abstract The ZUMA-7 (Efficacy of Axicabtagene Ciloleucel Compared to Standard of Care
Therapy in Subjects With Relapsed/Refractory Diffuse Large B Cell Lymphoma) study …

Context The cumulative impact of disease and treatment-related factors on health-related
quality of life (HRQoL) in long-term survivors of multiple myeloma is poorly characterized …

Background: First-line treatment of diffuse large B-cell lymphoma (DLBCL) achieves durable
remission in approximately 60% of patients. In relapsed or refractory disease, only about …

Objectives Among advanced multiple myeloma (MM) patients, B-cell maturation antigen
(BCMA) specific targets like Belantamab Mafodotin (belamaf) and CAR T-cell therapies have …

Background: Maintaining functional status is important to older adults with cancer, but data
are limited on how systemic treatments affect functional status. We systematically reviewed …

Autologous stem cell transplantation (ASCT) is an integral part of the frontline therapy in
eligible multiple myeloma (MM) patients. The impact of ASCT on health-related quality of life …

Quality of life (QOL) is increasingly recognized as an important clinical outcome of
hematopoietic cell transplantation (HCT), but patient education is often overlooked. The aim …